3) This program is intended for #healthcare providers and is supported by educational grants from Actelion, Bayer, Chiesi, & AstraZeneca. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/. Prior programs, still available for credit, are at cardiometabolic-ce.com
4) #PulmonaryEmbolism is common and the 3rd leading cause of cardiovascular death. But there are important long-term complications in those who survive acute PE, including #CTEPH. CTEPH can cause significant morbidity and mortality after #PE. Let’s start with a case!
5) A 67♀️ presents to #emergencymedicine with dyspnea x 3 months that acutely worsens for 3 days. PMHx significant only for #Hypertension. She has taken hydrochlorothiazide for years. She has no prior history of #PulmonaryEmbolism or #DVT.
6) On exam: Sats 91% on room air. HR 91, BP 110/75 . Her JVP is elevated at 6cm, there is mild edema. Lungs are clear and there is a parasternal heave. S2 is loud over the right upper sternal border🩺
7) Labs: D-dimer ⬆️, NT-proBNP⬆️at 2000 ng/L, T-wave inversion in V1-V6. A #CT pulmonary angio is done. See images below:
8) What do you see? There are bilateral filling defects in the proximal pulmonary arteries consistent with pulmonary embolism, but they have a “chronic” appearance to them. Geez, if only these scans always came with the red arrows!
9) Clot from acute PE tends to more central, similar to a “bulls-eye":
10) CTEPH occurs from incomplete resolution and fibrotic organization of thrombus leading to vascular obstruction. See 🔓pubs.rsna.org/doi/10.1148/rg…
11) Other CT features of #CTEPH include webs, bands, complete occlusions & focal stenoses. Calcification of thrombus ➡️ chronicity. Dilation of the pulmonary artery & RV & heterogenous attenuation of the lung (mosaic attenuation) are also often present 🔓doi.org/10.1016/j.heal…
And, for adding consideration of #moyamoya disease to your day . . . YOU ARE WELCOME
13) Time for a brief #Inception thread: A 🧵 within a 🧵! Why is it important to know about & recognize CTEPH? Here are3⃣ good reasons:
1⃣ CTEPH is not that rare! #PE is common. CTEPH occurs in ~ 1/30 or 3% of survivors of acute PE! (fig from 🔓erj.ersjournals.com/content/49/2/1…)
14) 2⃣ Untreated, #CTEPH carries a 70% mortality by 5 years! #CTEPH leads to progressive [Up arrow] in pulmonary pressure, dilation & failure of the #RightVentricle. Higher pressure = worse outcomes.
See doi.org/10.1378/chest.…
15) 3⃣ The most important reason to think about (and find) CTEPH is that effective treatments (and often a cure) exists…more on that later.
17) Back to our patient in the ED. She has signs of chronic PE and pulmonary hypertension on imaging & is hemodynamically stable. What is the most appropriate initial management?
A. Anticoagulation x 3 months
B. Thrombolysis
C. Catheter-directed thrombolysis
D. Thrombectomy
20) Yesterday's quiz? Scroll back⤴️to 17 if you didn't answer!
A. Anticoagulation for 3mos is best initial management. Diagnosing #CTEPH requires 1⃣ at least 3mos of effective anticoagulation 2⃣Pulmonary hypertension 3⃣Persistent obstruction on imaging. 🔓pubmed.ncbi.nlm.nih.gov/26320113/
21) Our patient in the ED likely has #CTEPH, given CT feature & symptom chronicity. In some cases, adequate course of anticoag can improve burden of thromboembolic disease. Close follow-up is required & patients who worsen or have right heart failure need urgent, definitive Rx.
22) Side note: it is always important to consider #CTEPH in a patient with #pulmonaryhypertension. Importantly, NOT all patients with CTEPH have prior history of #VTE. In a patient with #PH on #Echocardiogram, what is the best screening test to rule out #CTEPH? VOTE before ⤵️!
24) In the #PulmonaryHypertension diagnosis algorithm, VQ comes first, as the sensitivity is higher than CT. A normal VQ effectively rules out CTEPH.
25) Defects on VQ (top) suggests CTEPH but can’t differentiate acute from chronic clot. VQ-SPECT CT (bottom) improves Specificity by visualizing areas of parenchymal lung disease doi.org/10.1016/j.heal…
26) If the VQ is abnormal, the next step should be a CT pulmonary angiogram to confirm the presence of #CTEPH and to determine whether it is surgically operable.
28) PTE involves a sternotomy and cardiopulmonary bypass. Patients undergo deep hypothermia to protect neurologic function as the removal of thromboembolic material is done under full circulatory arrest. See 🔓consultqd.clevelandclinic.org/pulmonary-thro…
29) Once the thromboembolic material is removed, the pulmonary vascular resistance and pulmonary artery pressure are usually markedly lower and recovery can begin. An example of surgical specimen from PTE is below.
30) For patients able to successfully undergo PTE surgery, long-term survival is markedly better with >90% survival at 5-years. 🔓pubmed.ncbi.nlm.nih.gov/26826181/
31) Exercise capacity, quality of life and symptoms are also markedly improved after PTE. This figure shows rapid improvements in the #CAMPHOR questionnaire for a) activity b) quality of life and c) symptoms pubmed.ncbi.nlm.nih.gov/32513780/
32) PTE is major surgery that carries risks, but it's also potentially curative. Determining whether a patient is a good candidate for PTE req's multidisciplinary discussion in an expert #CTEPH surgical centre. Factors related to surgical suitability:🔓pubmed.ncbi.nlm.nih.gov/30545969/
33) So for patients unable or unwilling to undergo PTE surgery, which other treatment options can be considered?
A. Balloon pulmonary angioplasty (BPA)
B. Riociguat
C. Lung transplantation
D. All of the above
35) Welcome back! You are just a few 🖱️clicks away from 0.75h CE/#CME! And what a ride! @AlbertaPHdoc is teaching us ALL about #CTEPH--a big problem! Per 🔓pubmed.ncbi.nlm.nih.gov/28356407/, incidence of CTEPH in 🇫🇷🇩🇪🇮🇹🇪🇸🇬🇧🇺🇸🇯🇵 is dramatically ⤴️ing, as is severity at the time of dx.
36) Yesterday's quiz (tweet 33) answer is D. Some pts have distal disease in subsegmental vessels or in the pulmonary microcirculation that is inaccessible to surgery. Some are medically unable to undergo PTE due to comorbidities.
37) #Riociguat and/or #BPA are both options in such patients. Lung Tx can be considered in those with refractory #PH after medical Rx or BPA.
38) The choice of medical therapy with riociguat or BPA depends on the location of the #CTEPH lesions. Some patients receive a combination of PTE (a.k.a. PEA), BPA and medical therapy. 🔓erj.ersjournals.com/content/53/1/1…
39) Currently #riociguat is the only medical therapy approved by the @US_FDA for #CTEPH. Other studies tested #bosentan and #macitentan, but they are not approved (both are endothelin receptor antagonists used in pulmonary arterial hypertension). 🔓doi.org/10.1183/139930…
40) Riociguat is a soluble guanylate cyclase stimulator that increases #cGMP in pulmonary arteries leading to vasodilation and lower pulmonary vascular resistance. It acts independently of nitric oxide availability 🔓err.ersjournals.com/content/19/115…
41) In the CHEST-1 trial, riociguat improved 6-minute walking distance by 36 meters (36 m; 95% CI, 20 to 52 m) at 12 weeks vs placebo, which led to its approval for #CTEPH. See 🔓pubmed.ncbi.nlm.nih.gov/23883378/
43) #BPA is a catheter-based approach like coronary angioplasty where a wire crosses a #CTEPH lesion in a small segmental or subsegmental artery. A balloon is inflated to dilate and disrupt the obstructing lesion and improve blood flow.
🔓err.ersjournals.com/content/26/143…
44) Here is a video of a lower lobe BPA procedure with sluggish, minimal blood flow before ballooning and markedly improved blood flow afterwards.
45) Exercise intolerance in #CTEPH is multifactorial & other defects in the oxygen delivery and uptake pathway may contribute to impairment. Even after restoring or improving cardiac function, many patients have residual peripheral muscle dysfunction 🔓pubmed.ncbi.nlm.nih.gov/33853383/
46) These residual peripheral factors in #CTEPH highlight the role of #exercise training & #rehabilitation. Indeed, a recent RCT of exercise training showed improvements in exercise capacity as is seen with adding medical therapy! pubmed.ncbi.nlm.nih.gov/33232470/
47) There you go! In summary, #CTEPH is an important complication of #VTE but many patients have no prior history of #PE or #DVT. Always consider #CTEPH in a patient with #pulmonaryhypertension
1) Welcome to a 🆕 #accredited #tweetorial on #Albuminuria: The Canary in the Coal Mine of #Kidney and #Cardiorenal #Disease. Our returning expert author is the wonderful teacher Edgar V. Lerma 🇵🇭 @edgarvlermamd
#Cardiorenal #Nephpearls #nephtwitter #FOAMed #CardioTwitter
2) The program is intended for #HCPs & is supported by an independent educational grant from Bayer. Statement of accreditation and faculty disclosures at . Follow this 🧵for 0.75hr 🆓 CE/#CMEcredit--all delivered right here on X!cardiometabolic-ce.com/disclosures/
3) A canary in a coal mine is an advanced warning of danger. The term originates from when miners carried caged canaries while at work; if there was any methane or carbon monoxide in the mine, the canary would die before the levels of the gas reached those hazardous to humans.
1) Welcome to a 🆕#accredited #tweetorial on the challenges clinicians face when managing #venous #thromboembolism in patients with #cancer: cancer-associated thrombosis or #CAT. Our expert faculty is #shematologist Jean Connors MD @connors_md at @BrighamWomens & @DanaFarber.
2a) The program is intended for #healthcare professionals & supported by an independent educational grant from Anthos Therapeutics. Statement of accreditation & faculty disclosures at .cardiometabolic-ce.com/disclosures/
2b) Earn 0.5 hr 🆓CE/#CME by following this 🧵 & follow us for more expert-authored #MedEd. #FOAMed #ONCSM @MedTweetorials #CardioTwitter #cvCoag
🚨See prior programs in this area, still available for MedEd credit, at .cardiometabolic-ce.com/category/antit…
1) Welcome to the next installment of our #MedEd series on the potential for selective inhibitors of coagulation Factor XI or XIa (#FXI/#XIa) for therapeutic anticoagulation. Catch up with us by viewing & earn 🆓CE/#CMEcredit if you haven't already!cardiometabolic-ce.com/antithrombotic…
2) That prior program shared and explained the results of the #LBCT data from #AZALEA_TIMI_71 at #AHA23. Lots has happened in the #FXI world since then, so it's time revisit and recap.
3) It's always an honor when expert #cardiologist and incredible #researcher #educator C. Michael Gibson @CMichaelGibson pens an #accredited #tweetorial for us, but in particular we welcome his view on the most recent data and evolving thinking about #FXI inhibition.
1) Welcome to a 🆕#LIVE #accredited #tweetorial posted from #Toronto and #WSC2023, where we have just seen top-line results of #ANNEXa_I, the FIRST randomized comparison between #andexanet_alfa & usual care in pts with anti-#FXa #DOAC-associated #ICH.
2) Our expert author is #ANNEXa_I investigator Ashkan Shoamanesh MD @Ash_Shoamanesh, #Stroke #Neurologist @HamHealthSci, Assoc Prof @McMasterU, & Director of Hemorrhagic Stroke Research Program & Scientist @PHRIresearch #FOAMed #FOAMcc #neurotwitter #cardiotwitter #MedEd
3) This program is supported by an independent educational grant from AstraZeneca. Statement of accreditation & faculty disclosures at . FOLLOW @cardiomet_ce for more expert-led 🆓CE/#CME delivered wholly on Twitter!cardiometabolic-ce.com/disclosures/
1a) Welcome to a 🆕#accredited tweetorial on Analyzing Safety Data for #siRNA for Lowering #LDL-C and #Lp(a). Our expert faculty is James A. Underberg, MD, MS, FACPM, FACP, MNLA @lipiddoc
#Cardiotwitter #FOAMed
1b) @lipiddoc is a #lipidologist🩺🧬@nyulangone @NYUCVDPrevent. He is President of the Foundation of @nationallipid, Past-President of both @nationallipid AND @LipidBoard, and is Director of @BHLipidClinic. @cardiomet_CE is proud to welcome @lipiddoc as new faculty!
2) This presentation was originally delivered by @lipiddoc at an accredited satellite symposium at @nationallipid's June 2023 congress. He shared the podium there with lipidology & #preventive #cardiology experts @alanbrownmd, @jpenamd, & @NP_ltl_a.
@MedTweetorials
1) Welcome to a 🆕#accredited tweetorial on Recent Advances in the Risk Assessment in Patients with Hyperlipidemia: Enhancing Precision and Reliability. Our expert faculty is Dr Nataliya Pyslar @NP_ltl_a, #Cardiologist& Lipid Specialist @CookCtyHealth.
#Cardiotwitter #FOAMed
2) This presentation was originally delivered by @NP_ltl_a at an accredited satellite symposium at @nationallipid's June 2023 congress. She shared the podium there with lipidology & #preventive #cardiology experts @alanbrownmd, @jpenamd, & @lipiddoc.
@MedTweetorials
3a) The symposium and this tweetorial were supported by an unrestricted educational grant from Novartis. Statement of accreditation & faculty disclosures at .cardiometabolic-ce.com/disclosures/